Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2017

View Archived Issues

ObsEva initiates phase III for nolasiban in ART

FDA accepts for filing Vraylar sNDA for maintenance treatment of schizophrenia

Cellceutix reports interim results from phase IIa trial of brilacidin in ulcerative colitis

FDA awards QIDP designation to Polypid's D-PLEX

Novel mouse model for evaluating the role of MMP7 in epithelial integrity and ciliogenesis in IPF

miRNAs as novel prognostic biomarkers in MGMT unmethylated glioblastomas

European orphan drug designation granted to CUR-1916 for Dravet syndrome

UMass Memorial Medical Center presents novel epigenetic biomarker data

Phase III NAVIGATE data for guselkumab presented at AAD meeting

Nicox resubmits NDA for AC-170

Significant efficacy seen with sarecycline in facial acne vulgaris

3-V Biosciences discloses novel mTOR and/or PI3K inhibitors

FDA accepts sBLA for Soliris in refractory generalized myasthenia gravis

SBIR grants supports CerSci's development of non-opioid drug candidates to treat neuropathic pain

FDA accepts sNDA for Auryxia

HNF-3A, a promising biomarker for the diagnosis of medullary thyroid carcinoma

Medshine Discovery patents vinyl compounds as FGFR and VEGFR inhibitors

TiGenix reports promising 2-year data from ADMIRE-CD study of Cx-601

Opthea discusses proposed phase IIb study of OPT-302 with FDA

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine develop IDO-1 inhibitors

Apricus completes sale to Ferring of Vitaros ex-U.S. rights

BerGenBio collaborates with Merck & Co. to study BGB-324 with pembrolizumab

Capnia completes merger with Essentialis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...